首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1629686

心源性休克治療市場：依治療類型、最終用戶、地區

Cardiogenic Shock Treatment Market, By Treatment Type, By End User, By Geography

出版日期: 2024年11月27日 | 出版商:

Coherent Market Insights | 英文 161 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球心源性休克治療市場規模為11億美元，預計2031年將達17.8億美元，2024年至2031年複合年成長率為7.1%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	11億美元
實際資料	2019-2023	預測期	2024-2031
預測 2024-2031 年複合年成長率：	7.10%	2031年價值預測	17.8億美元

圖：2024 年按地區分類的心源性休克治療市場佔有率(%)

心源性休克是一種危及生命的疾病，心臟突然停止泵送足夠的血液來滿足身體的需求。這種疾病可能是由心臟病發作、心血管手術後的併發症和心肌感染疾病等情況引起。如果不及時治療，可能會迅速發生器官衰竭並導致死亡。全球心血管疾病的增加以及對複雜心臟疾病有效管理的需求不斷增加是預計未來幾年推動全球心源性休克治療市場成長的主要因素。

市場動態：

全球心源性休克治療市場主要是由冠狀動脈疾病、心臟病和心臟衰竭等心血管疾病的盛行率不斷上升所推動的。根據世界衛生組織 (WHO) 統計，2021 年 6 月，心血管疾病是全球第一大死因，估計每年奪走超過 1,790 萬人的生命。此外，市場的成長也受到越來越多的老年人的支持，他們更有可能患上這種嚴重的心臟疾病。機械循環支援設備各種技術的進步以及這些有效管理方案的快速採用正在提供新的機會。然而，與設備和外科手術相關的高成本阻礙了低收入地區的市場滲透。此外，公眾缺乏對早期診斷和管理方案的認知也是一個挑戰。

本研究的主要特點

該報告對全球心源性休克治療市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。

根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球心源性休克治療市場的主要企業進行了分析。

本研究涵蓋的主要企業包括 Abbott、Medtronic、Getinge AB、Abiomed、Terumo Corporation、Boston Scientific、F. Hoffmann-La Roche Ltd、Bayer AG、Viatris Inc.、Par Pharmaceutical、AstraZeneca、Zoll Medical Corporation，其中包括 Xenios AG （Fresenius Medical Care 的一部分）、Windtree Therapeutics 和Chiesi Farmaceutici SpA。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球心源性休克治療市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球心源性休克治療市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.10 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	7.10%	2031 Value Projection:	US$ 1.78 Bn

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's need. This failure can result from conditions like heart attack, complications after heart surgery, or heart muscle infection. Without prompt treatment it can rapidly lead to organ dysfunction and death. Globally rising cases of cardiovascular diseases and increasing demand for effective management of complex cardiac conditions are the major factors anticipated to boost the growth of the cardiogenic shock treatment market worldwide in the coming years.

Market Dynamics:

The global cardiogenic shock treatment market is primarily driven by the increasing prevalence of cardiovascular diseases such as coronary artery disease, heart attacks, and heart failures. According to the World Health Organization, in June 2021, cardiovascular diseases are the leading cause of deaths globally, taking an estimate of over 17.9 million lives each year. Moreover, rising geriatric population susceptible to develop such critical cardiac conditions also supports the market growth. Various technological advancements in mechanical circulatory support devices and rapid adoption of these effective management options offer new opportunities. However, high cost associated with devices and surgical procedures hampers market penetration in low-income regions. Additionally, lack of awareness among people about early diagnosis and management options pose challenges.

Key Features of the Study:

This report provides in-depth analysis of the global cardiogenic shock treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global cardiogenic shock treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global cardiogenic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiogenic shock treatment market

Market Segmentation

Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Mechanical Support Devices
- Pharmacological Treatments:
- Surgical Procedures
- Others
End User Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Cardiac Care Centers
- Ambulatory Surgical Centers
- Others
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Abbott
- Medtronic
- Getinge AB
- Abiomed
- Terumo Corporation
- Boston Scientific
- F.Hoffmann-La Roche Ltd
- Bayer AG
- Viatris Inc.
- Par Pharmaceutical
- AstraZeneca
- Zoll Medical Corporation
- Xenios AG (part of Fresenius Medical Care)
- Windtree Therapeutics
- Chiesi Farmaceutici S.p.A.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Cardiogenic Shock Treatment Market, By Treatment Type
- Global Cardiogenic Shock Treatment Market, By End User
- Global Cardiogenic Shock Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Cardiogenic Shock Treatment Market, By Treatment Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mechanical Support Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pharmacological Treatments:
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Surgical Procedures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Cardiogenic Shock Treatment Market, By End User, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cardiac Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Cardiogenic Shock Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Abbott
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Getinge AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abiomed
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Terumo Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boston Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F.Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Par Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zoll Medical Corporation
Xenios AG (part of Fresenius Medical Care)
Windtree Therapeutics
Chiesi Farmaceutici S.p.A.